Table 2. Minimum Residual Disease Negativity With Complete Response at End of Induction: Response Rates and Durability of Response^a.

Outcomes	Ponatinib (n = 154)	Imatinib (n = 78)	Risk difference (95% CI)	Relative risk (95% CI)	P value
Primary end point: MRD-negative complete remission at end of induction, No. (%)b	53 (34.4)	13 (16.7)	0.18 (0.06-0.29)	2.06 (1.19-3.56)c	.002c
MRD negativity (MR4) at end of induction, No. (%)	61 (43.0)d	15 (22.1)d	0.21 (0.08-0.34)	1.94 (1.19-3.17)c	.002c
Duration of MRD-negative complete remission	n = 53	n = 13
Loss-of-response events, No. (%)	9 (17.0)	6 (46.2)
Duration, median (95% CI), mo	NE (16.6-NE)	18.0 (8.4-27.8)	NA	NA

Abbreviations: MRD, minimal residual disease; NA, not available; NE, not estimable.

^a Outcomes were evaluated in the population of patients in the intention-to-treat population with p190/p210 dominant isoforms confirmed by the central laboratory.

^b The composite primary end point required central laboratory–reported MRD negativity (defined as ≤0.01% BCR::ABL1^IS [MR4]) and investigator-reported complete remission (bone marrow blast response with hematologic recovery as measured by absolute neutrophil and platelet counts) for ≥4 weeks at the end of induction.

^c Adjusted relative risks, 95% CIs, and P values were calculated based on a Cochran-Mantel-Haenszel χ² test, with stratification according to randomization strata (ages 18 to <45 years, ≥45 to <60 years, and ≥60 years).

^d Among patients with evaluable samples at end of trial cycle 3 (n = 142 for ponatinib and n = 68 for imatinib).